Utility of Contact Investigation of Drug Susceptible and Resistant TB in Tanzani

坦桑尼亚药物敏感和耐药结核病接触者调查的效用

基本信息

批准号：
8514469
负责人：
Elizabeth Fair
金额：
$ 12.4万
依托单位：
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
依托单位国家：
美国
项目类别：
财政年份：
2009
资助国家：
美国
起止时间：
2009-09-18 至 2015-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8514469
关键词：
Address Africa Africa South of the Sahara Applications Grants Area Award Budgets California Capital Caring Cause of Death Cities Clinical Research Cohort Studies Communities Cost Effectiveness Analysis Cost Measures Country Critical Care Data Detection Developing Countries Development Plans Disease Disease Outbreaks Drug Resistant Tuberculosis Drug resistance Drug resistance in tuberculosis Drug-sensitive Early Diagnosis Early identification Economics Emergency Situation Enrollment Epidemic Epidemiologist Epidemiology Evaluation Extreme drug resistant tuberculosis Family Foundations Funding Future Genotype Goals Gold HIV HIV Infections Health Personnel High Prevalence Household Incidence Incidental Findings Infection Institutes International Interruption Intervention Investigation Isoniazid resistance Knowledge Laboratories Laboratory Research Learning Leprosy Life Low income Lung Measures Medical Research Medicine Mentors Methods Mutation Mycobacterium tuberculosis Organism Participant Pathogenicity Patient Education Patients Pattern Persons Pharmaceutical Preparations Policy Developments Predisposition Prevalence Preventive Intervention Principal Investigator Process Public Health Publishing Pulmonary Tuberculosis Relapse Research Research Personnel Research Technics Resistance Resources Restriction fragment length polymorphism Retreatment San Francisco Science Source Speed Sputum Tanzania Testing Time Training Treatment Failure Tuberculosis Universities Work World Health Organization authority base career career development case finding cost cost effective cost effectiveness design diagnosis standard disability disease transmission disorder control evidence base high risk indexing indium arsenide innovation isoniazid mathematical model novel strategies programs prospective public health emergency resistant strain screening therapy design transmission process tuberculosis treatment

项目摘要

This is an application for a KOI, award for Dr. Elizabeth Fair, an epidemiologist in the Division of Pulmonary and Critical Care Medicine at the University of California, San Francisco. Dr. Fair is establishing herself as an investigator in epidemiologic and cost effectiveness analyses to evaluate the feasibility, cost, and impact of new tuberculosis (TB) case detection methods in resource limited-settings with high incidences of TB and HIV and increasing threats of drug-resistant TB. This KOI award will provide Dr. Fair with the support necessary to accomplish the following goals: (1) to become expert in applying advanced analytic methods for evaluating the cost effectiveness of programmatic TB interventions; (2) to learn to apply mathematical modeling of infectious disease transmission for evaluating the impact of TB interventions; (3) to become expert in the design, enrollment, and management of a prospective cohort study in a low resource setting; (4) to apply laboratory research techniques for TB genotyping and drug resistance testing; and (5) to develop and independent clinical research career. To achieve these goals. Dr. Fair has assembled a mentoring team comprised of a primary mentor. Dr. Philip Hopewell, an internationally recognized authority on global TB control, and 2 co-mentors: Dr. James G. Kahn, an internationally recognized expert on cost effectiveness studies, .and Dr. Travis Porco, a well-published mathematical modeler and epidemiologist, Low case finding of new TB patients is a major limitation to global control of the disease, especially in high HIV-prevalence areas. Dr. Fair's research will determine whether household contact investigation in a low-income, high TB burden setting results in earlier diagnosis of TB (Aim 1)..She will also assess the costs, cost-effectiveness, and impact of contact investigation under program conditions (Aim 2); and characterize the transmissibility and pathogenicity of M.tb strains from new cases found through household contact investigation (Aim 3). The research will form the basis for a future R01 grant application to address the scientific basis of TB transmission and pathogenicity, specifically of drug-resistant M.tb strains.

这是锦鲤的申请，是伊丽莎白·费尔博士奖，伊丽莎白·博伊德博士是旧金山分校肺和重症监护医学科的流行病学家。 Fair博士正在建立自己是流行病学和成本效益分析的研究者，以评估新的结核病（TB）病例检测方法的可行性，成本和影响的资源限量性限制方法，其TB和HIV发生率很高，并增加了耐药性TB的威胁。该锦护奖将为Fair博士提供实现以下目标所需的支持：（1）成为应用高级分析方法的专家，以评估程序化结核病干预措施的成本效益；（2）学习应用传染病传播的数学模型来评估结核病干预措施的影响；（3）成为在低资源环境中的潜在队列研究的设计，入学和管理专家；（4）将实验室研究技术应用于结核病基因分型和耐药性测试；（5）发展和独立的临床研究职业。实现这些目标。 Fair博士组建了一个由主要导师组成的指导团队。菲利普·霍普威尔（Philip Hopewell）博士是全球结核病控制权的国际认可的权威，以及2位联合委员：詹姆斯·G·卡恩（James G. Fair博士的研究将确定家庭接触调查是否在低收入，高结核病负担设置中导致早期诊断为结核病（AIM 1）。她还将评估计划条件下的成本，成本效益和联系调查的影响（AIM 2）；并表征通过家庭接触调查发现的新病例的M.TB菌株的可传播性和致病性（AIM 3）。这项研究将构成未来R01赠款应用程序的基础，以解决TB传播和致病性的科学基础，特别是耐药性M.TB菌株的基础。